Search Within

Min Yuen Teo

  1. "Body Imaging Service"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (5)
Groups
  1. Body Imaging Service (12)
  2. Department of Medicine (12)
  3. Genitourinary Oncology Service (12)
  4. Radiology, Department of (12)
  5. Solid Tumor Oncology Division (12)
  6. Weinberg Fellows (11)

More Groups

People
  1. Gopakumar Iyer (10)
  2. Dean Bajorin (9)
  3. Jonathan Rosenberg (9)
  4. Samuel Funt (9)
  5. Ashley Regazzi (8)
  6. Chung-Han Lee (7)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (2)
  4. 2021 (1)
  5. 2020 (3)
  6. 2019 (2)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Cancer Imaging (1)
  3. Cancer Medicine (1)
  4. Journal for ImmunoTherapy of Cancer (1)
Publishers
  1. American Society of Clinical Oncology (9)
  2. Biomed Central Ltd (2)
  3. Wiley Blackwell (1)

Results (12)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Badri, A.; Guercio, B. J.; Ratna, N.; Gavrilov, D.; Metzker, N.; Duzgol, C.; Teo, M. Y.; Regazzi, A. M.; Supplice, L.; Funt, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Bajorin, D. F.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: Diagnostic performance and outcomes using biparametric vs. multiparametric MRI
    Journal Article

    Woo, S.; Becker, A. S.; Das, J. P.; Ghafoor, S.; Arita, Y.; Benfante, N.; Gangai, N.; Teo, M. Y.; Goh, A. C.; Vargas, H. A.
    Cancer Imaging (2023)

    Fulltext@MSK | Save
  • Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Guercio, B. J.; Ratna, N.; Gavrilov, D.; Duzgol, C.; Akhlaq, M.; Teo, M. Y.; Regazzi, A. M.; Kotecha, R. R.; Funt, S. A.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
    Journal Article

    Sarfaty, M.; Whiting, K.; Teo, M. Y.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Jungbluth, A. A.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
    Journal Article

    Ged, Y.; Chaim, J. L.; DiNatale, R. G.; Knezevic, A.; Kotecha, R. R.; Carlo, M. I.; Lee, C. H.; Foster, A.; Feldman, D. R.; Teo, M. Y.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Meeting Abstract

    Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Cancer susceptibility mutations in patients with urothelial malignancies
    Journal Article

    Carlo, M. I.; Ravichandran, V.; Srinavasan, P.; Bandlamudi, C.; Kemel, Y.; Ceyhan-Birsoy, O.; Mukherjee, S.; Mandelker, D.; Chaim, J.; Knezevic, A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save